Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - turoctocog alfa - powder and solvent for solution for injection - turoctocog alfa 500 iu / 4 ml - coagulation factor viii - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor viii deficiency).novoeight can be used for all age groups.

Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - insulin aspart - solution for injection - insulin aspart 100 u/ml - insulin aspart - treatment of patients with diabetes mellitus in adults, adolescents and children aged 2 years and above.

Iirimaa - inglise - HPRA (Health Products Regulatory Authority)

novo nordisk a/s - estradiol; norethisterone acetate; estradiol - film-coated tablet - %v/v - progestogens and estrogens, fixed combinations; norethisterone and estrogen

Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - estradiol as hemihydrate; norethisterone acetate - film coated tablets - estradiol as hemihydrate 1 mg; norethisterone acetate 1 mg - estradiol, combinations - estradiol, combinations - hormone replacement therapy (hrt) for estrogen deficiency symptoms in postmenopausal women with an intact uterus. prevention of osteoporosis in postmenopausal women at high risk of future fractures, who are tolerant of , or contraindicated for other medicinal products approved for the prevention of osteoporosis.the experience treating women older than 65 years is limited.

Austraalia - inglise - Department of Health (Therapeutic Goods Administration)

novo nordisk pharmaceuticals pty ltd - catridecacog, quantity: 5.25 mg/ml - drug delivery system - excipient ingredients: - novothirteen is indicated for routine prophylaxis of bleeding in patients with congenital factor xiii a-subunit deficiency.

Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - repaglinide - tablets - repaglinide 0.5 mg - repaglinide - repaglinide - repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in adults with type 2diabetes mellitus who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - repaglinide - tablets - repaglinide 1 mg - repaglinide - repaglinide - repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

Iisrael - inglise - Ministry of Health

novo nordisk ltd., israel - repaglinide - tablets - repaglinide 2 mg - repaglinide - repaglinide - repaglinide is indicated in adults with type 2 diabetes mellitus whose hyperglycaemia can no longer be controlled satisfactorily by diet, weight reduction and exercise. repaglinide is also indicated in combination with metformin in adults with type 2 diabetes mellitus who are not satisfactorily controlled on metformin alone.treatment should be initiated as an adjunct to diet and exercise to lower the blood glucose in relation to meals.

Euroopa Liit - inglise - EMA (European Medicines Agency)

novo nordisk a/s - insulin aspart - diabetes mellitus - drugs used in diabetes - novorapid is indicated for treatment of diabetes mellitus in adults, adolescents and children aged 1 year and above.

Euroopa Liit - inglise - EMA (European Medicines Agency)

novo nordisk a/s - eptacog alfa (activated) - hemophilia b; thrombasthenia; factor vii deficiency; hemophilia a - antihemorrhagics - novoseven is indicated for the treatment of bleeding episodes and for the prevention of bleeding in those undergoing surgery or invasive procedures in the following patient groups:in patients with congenital haemophilia with inhibitors to coagulation factors viii or ix > 5 bethesda units (bu);in patients with congenital haemophilia who are expected to have a high anamnestic response to factor-viii or factor-ix administration;in patients with acquired haemophilia;in patients with congenital factor-vii deficiency;in patients with glanzmann's thrombasthenia with antibodies to platelet glycoprotein (gp) iib-iiia and / or human leucocyte antigens (hla), and with past or present refractoriness to platelet transfusions.in patients with glanzmann’s thrombasthenia with past or present refractoriness to platelet transfusions, or where platelets are not readily available.